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Angiogenesis is an essential process in tumor growth.  The concept of angiogenesis,  when proposed by 
Folksman in 1971,  had a great impact on cancer research and therapy,  as the survival and prolifera-
tion of cancer depend on angiogenesis,  which could be a target of cancer therapy.  In subsequent 
decades,  numerous antiangiogenic agents were developed,  and some of them have been applied clini-
cally.  However,  angiogenesis includes a complex and multistep process that has not been suﬃciently 
elucidated.  In this review,  we focus on signaling pathways related with tumor angiogenesis and sev-
eral antiangiogenic agents approved by the United States Food and Drug Administration or under 
investigation.
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olecular targeted therapy has become a main-
stay in cancer therapy,  most often targeting 
small molecules expressed by cancer cells (e.g.,  
EGFR,  epidermal growth factor receptor; HER2,  
human epidermal growth factor receptor 2; BCR-
ABL,  breakpoint cluster region-Abelson murine leu-
kemia viral oncogene homolog 1 and Kit) that are 
closely related to carcinogenesis and drive the tumor 
growth.  This strategy targets cancer cells themselves,  
and its use has resulted in a dramatic beneﬁt in a 
certain subset of patients,  though it has some critical 
problems,  such as acquired resistance to molecular 
targeted agents,  that indicate the diﬃculty of using the 
strategy to cure advanced cancer.
　 In recent years,  the concept of a tumorʼs microen-
vironment associated with treatment sensitivity has 
gained attention.  It has been known for a long time 
that tumors need abundant vessels for their growth.  
Folksman et al.  presumed in 1971 that survival and 
proliferation of cancer depend on angiogenesis,  which 
could be a target of cancer therapy [1].  According to 
them,  tumors can initially grow by capturing oxygen 
and nutrition via diﬀusion from the surrounding 
microenvironment,  but they cannot grow beyond 2mm 
without angiogenesis [2].  Therefore,  tumors secrete 
various pro-angiogenic factors for angiogenesis.  In 
many aspects,  tumor vessels are diﬀerent from normal 
vessels.  They are dilated,  tortuous,  and poorly cov-
ered with pericytes [3,  4].  This immature structure 
causes hyperpermeability of these vessels and elevated 
interstitial pressure resulting in insuﬃcient blood ﬂow,  
which might impair drug delivery to the tumors.
　 The term “angiogenesis” means the expansion of a 
vascular network by branching new vessels from exist-
ing ones,  which is diﬀerentiated from “vasculogene-
sis, ” meaning de novo vascular formation at an avascu-
lar area chieﬂy in the embryonic stage.  Angiogenesis 
is a complex physiological process.  After the stimulus 
of various pro-angiogenic factors,  including vascular 
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endothelial growth factor (VEGF),  which is described 
below,  angiogenesis begins with the detachment of 
mural cells and local proteolysis of the vessel wall.  
Next,  endothelial cells begin to proliferate and 
migrate,  followed by sprouting and branching of new 
vessels.  The endothelial cell at the front of the 
sprouting is called the “tip cell, ” and it is distin-
guished functionally and phenotypically from the 
endothelial cells existing at the lateral side,  which are 
called “stalk cells. ” Finally,  new vessels are matu-
rated by covering mural cells.
　 In this manuscript,  we ﬁrst describe the major 
signaling pathways related to tumor angiogenesis,  and 
we then describe the clinical application of targeting 
angiogenesis.
VEGF/Vascular Endothelial Growth Factor 
Receptor (VEGFR) (Fig.  1A)
　 VEGF-A. In 1983,  Senger et al.  discovered a 
small molecule inducing vascular leakage in a guinea-
pig cell line and named it vascular permeability factor 
(VPF) [5].  Ferrara et al.  isolated and cloned VEGF,  
which induces proliferation of endothelial cells,  in 
1989 [6].  Later,  VEGF and VPF turned out to be 
the same molecule.  VEGF has gene family members 
including VEGF-A,  -B,  -C,  -D,  and -E and placental 
growth factor (PlGF) [7].  Among them,  VEGF-A has 
been the most characterized and is considered a key 
angiogenic factor with various splicing variants such 
as VEGF-A125,  -A145,  -A165,  -A183,  -A189,  and -A206 
[8-10].  The term “VEGF” often refers to VEGF-A.  
VEGF-A is indispensable during embryonic vascular 
development,  and even the loss of a single VEGF-A 
allele results in embryonic lethality with defective 
vasculature in a mouse model [11,  12].  Hypoxia,  
often seen in the center of tumors,  strongly up-regu-
lates VEGF-A expression via increased hypoxia 
inducible factor (HIF) [13].  Under normal conditions,  
HIF is ubiquitinated and degenerated by binding to von 
Hippel-Lindau (VHL) protein,  but,  in the hypoxic 
condition,  HIF cannot bind to VHL,  resulting in 
increased HIF.  Increased HIF binds to the DNA chain 
at the HIF-1 binding site,  the hypoxia response ele-
ment (HRE),  and enhances many pro-angiogenic gene 
transcriptional activities,  including that of the 
VEGF-A gene [13].
　 VEGFR. VEGF family members bind to 
VEGFR (VEGFR-1,  VEGFR-2,  and VEGFR-3).  
VEGF-A binds to VEGFR-1 and VEGFR-2 [14].  
Although the aﬃnity of VEGF-A to VEGFR-1 is 
10-fold higher than that to VEGFR-2,  VEGF-A sig-
naling is mainly mediated by VEGFR-2 because of its 
intense kinase activity [15,  16].  VEGFR-2 signaling 
in endothelial cells is mediated to downstream cas-
cades such as PI3K/AKT,  p38/MAPK,  and PLCγ/
MAPK,  causing proliferation and migration of 
endothelial cells,  production of proteases,  and hyper-
permeability of vessels [17,  18].  Currently,  research-
ers agree that VEGF-A/VEGFR-2 signaling is the key 
pathway the mediates tumor angiogenesis.
　 VEGF-B and PlGF bind only to VEGFR-1,  in 
contrast to VEGF-A,  which binds to both VEGFR-1 
and -2 [19].  VEGFR-1 signaling has more complex 
roles in angiogenesis compared with that of VEGFR-
2.  VEGFR-1 exists as a decoy receptor with high 
aﬃnity to VEGF-A and little kinase activity prevent-
ing VEGF-A from binding to VEGFR-2 [14],  so 
VEGFR-1 works as a negative regulator of angiogen-
esis.  In fact,  VEGFR-1 tyrosine kinase-deﬁcient 
mice,  with normal ligand binding ability and deﬁcient 
signal transduction,  developed normally [20],  which 
means VEGFR-1 tyrosine kinase activity is not indis-
pensable,  at least during development.  On the other 
hand,  there is growing evidence that VEGFR-1 can 
mediate its ligand signals to downstream cascades.  
VEGFR-1 signaling in bone marrow cells such as 
macrophage lineage cells mobilized them to the tumor 
tissues,  contributing to angiogenesis and tumor pro-
gression in a subcutaneous injected tumor model [21].  
It has also been reported that VEGFR-1 signaling 
might be associated with metastasis [22,  23].
　 VEGFR-3 is reported to induce lymphangiogenesis 
after binding VEGF-C or -D [24,  25].  Lymphan-
giogenesis plays another important role in the tumor 
microenvironment and is considered the ﬁrst step of 
tumor metastasis.
Angiopoietin/Tie2 (Fig.  1B)
　 Angiopoietin (Ang). Ang/Tie2 signaling is an 
endothelial cell-speciﬁc pathway,  like VEGF/VEGFR 
signaling,  but it is diﬃcult to target for cancer ther-
apy because of its complex system,  as we will discuss 
later.  Angiopoietins play an important role in vessel 
stabilization and maturation,  though they cannot 
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directly induce tumor angiogenesis [26,  27].  Angio-
poietins were identiﬁed in the 1990s.  The human 
angiopoietin family includes three angiopoietins,  Ang-
1,  Ang-2,  and Ang-4 [28],  all of which act as ligands 
for endothelial cell-speciﬁc tyrosine kinase receptor 
Tie2 [29-31].  To date,  research has mainly focused 
on Ang-1 and -2.
　 Ang-1,  expressed in many adult tissues,  binds to 
Tie2 receptor as an agonist and causes Tie2 autophos-
phorylation,  resulting in a facilitated connection 
between endothelial cells and mural cells [32].  Under 
physiological conditions,  mural cells,  including vascu-
lar smooth muscle cells and pericytes,  constantly 
produce Ang-1 and maintain vascular stabilization and 
maturation.  A recent study,  however,  reported a 
conﬂicting role of Ang-1,  which was that Ang-1 pro-
motes angiogenesis in some circumstance [33].  That 
is,  Ang-1/Tie2 signaling promotes endothelial cell 
proliferation when endothelial cells are isolated,  in 
contrast with promoting vessel stabilization when 
endothelial cells contact each other.
　 Ang-2,  predominantly expressed in angiogenic ves-
sels,  acts as an antagonist for Tie2 by competing with 
Ang-1 [30],  where it induces vascular destabilization 
and increased angiogenesis.  But the role of Ang-2 
seems to be altered by VEGF-A.  In the presence of 
endogenous VEGF-A,  Ang-2 increases tumor angio-
genesis by promoting vessel destabilization,  whereas 
Ang-2 promotes endothelial cell death and vessel 
regression in the absence of VEGF-A [34].  As noted 
above,  angiopoietins play very complex roles in angio-
genesis and antiangiogenesis.
　 Tie2. Tie1 and Tie2 receptors are endothelial 
cell-speciﬁc receptors expressed in vascular and lym-
phatic endothelial cells.  There is no ligand identiﬁed 
for Tie1 receptor [28,  35].  Many tyrosine kinase 
receptors form dimerization during ligands binding,  
but Tie2 forms dimerization or multimerization on 
Ang-1/Ang-2 binding [36].  Although the Ang/Tie2 
pathway has very complex roles,  because agonistic and 
antagonistic ligands bind to the same receptor,  block-
ing the Tie2 pathway in mouse models reduced tumor 
vascularization and growth [37,  38].
Platelet-derived Growth Factor (PDGF)/
Platelet-derived Growth Factor Receptor 
(PDGFR) (Fig. 1C)
　 PDGF. PDGF was ﬁrst identiﬁed in 1974 
[39].  Thus far,  four PDGF family members have 
been identiﬁed,  PDGF-A,  -B,  -C,  and -D [40].  
They form 5 kinds of homodimers and heterodimers,  
PDGF-AA,  -AB,  -BB,  -CC,  and -DD [40].  PDGFs 
generally act in a paracrine manner in a physiological 
condition or in epithelial cancers,  whereas they act in 
an autocrine manner in gliomas,  sarcomas,  and leuke-
mia [40].  PDGFs are secreted from various cells 
[40].  PDGF-A and -C are mainly secreted from epi-
thelial cells,  muscle,  and neuronal progenitors.  
PDGF-B is secreted from vascular endothelial cells.  
PDGF-D secretion is not well understood.
　 PDGFR. PDGFs transmit their signal via 
PDGFRs.  On binding PDGFs,  PDGFR dimerizes,  
autophosphorylates at the tyrosine residues in the 
intracellular domain [41],  and activates downstream 
pathways,  including PI3K,  Ras-MAPK,  and PLCγ 
[40].  There are 2 types of PDGFRs,  PDGFR-α and 
PDGFR-β [42].  PDGFRs can form 3 kinds of 
homodimers and heterodimers,  PDGFR-αα,  -ββ,  and 
αβ.  Considering the ﬁve PDGF dimers described above,  
there could be multiple and complex PDGF/PDGFR 
pairings.  To date,  however,  there are only three 
PDGF/PDGFR pairs proven to be functional in vivo,  
PDGF-AA/PDGFR-αα,  PDGF-CC/PDGFR-αα,  and 
PDGF-BB/ PDGFR-ββ [40].  PDGFR-α is involved 
in embryonic development,  and PDGFR-β is involved 
in angiogenesis.
　 The PDGFR-α-induced pathway is involved in 
organogenesis such as alveogenesis,  villus morpho-
genesis,  hair morphogenesis,  and oligodendrogenesis 
[40].  In addition,  PDGFR-α might indirectly pro-
mote angiogenesis by recruiting stromal ﬁbroblast-
producing VEGF-A and other pro-angiogenic factors 
[43].
　 PDGFR-β signaling is involved in angiogenesis.  
PDGFR-β expression is found in pericytes but not in 
endothelial cells.  Because of this,  the PDGFR-β 
signaling pathway does not increase the tumor vessels 
themselves but maturates tumor vessels by recruiting 
PDGFR-β-expressing pericytes,  accelerating tumor 
growth [44].  Blocking the PDGFR-β pathway inhib-
its matured vessels,  eliciting detachment of pericytes 
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and disruption of tumor vessels,  whereas blocking the 
VEGFR pathway impairs early-stage immature vessels 
lacking pericyte coverage but not large,  well-covered 
vessels [45].
Delta-like Ligand 4 (DLL4) /Notch (Fig.  1D)
　 DLL4. If pro-angiogenic factors such as 
VEGFR-2 signaling stimulated all the endothelial 
cells,  too much sprouting and branching would occur 
and the vascular structure itself would be destroyed.  
In fact,  not all of the endothelial cells are stimulated,  
due to a mechanism deciding which endothelial cells 
should react to angiogenic stimulus and which should 
not.  The DLL4/Notch pathway plays a key role in 
this mechanism.
　 DLL1,  DLL3,  DLL4,  Jagged1,  and Jagged2 bind 
to Notch receptor as ligands.  Among these ligands,  
DLL4 has been the most intensely investigated in the 
area of tumor angiogenesis,  because DLL4 is strongly 
expressed in tumor vascular endothelial cells but more 
weakly in normal vascular endothelial cells [46,  47].  
DLL4 is a transmembrane ligand,  and its expression 
in tumor vessels is regulated by VEGF-A.  VEGF-A 
up-regulates DLL4 in the sprouting endothelial cells 
(tip cells),  and up-regulated DLL4 interacts with 
Notch in the adjacent endothelial cells (stalk cells) 
[48,  49].  In reverse,  the DLL4/Notch pathway 
down-regulates VEGFR-2 expression in Notch 
expressing endothelial cells,  resulting in the reduction 
of VEGF-A-induced sprouting and branching [49].  
Thus the DLL4/Notch pathway can be considered a 
negative feedback system of the VGFR pathway.
　 Notch. Notch receptors are single-pass trans-
membrane proteins in a family consisting of Notch1,  
Notch2,  Notch3,  and Notch4.  The Notch receptor 
signaling pathway has a characteristic mechanism for 
transduction of its signaling [50].  After the ligand 
binding,  Notch receptor is cleaved at the extracellu-
lar domain by proteases such as ADAM10 or TACE,  
followed by the cleavage at the transmembrane domain 
by γ-secretase.  As a consequence,  Notch intracellu-
lar domain translocates to the nucleus and activates 
the transcription of target genes.
　 Blocking the DLL4/Notch signaling pathway leads 
to increased angiogenesis,  such as the enhancement of 
tip-cell formation,  branching,  and vessel density.  
Paradoxically,  blockade of the DLL4/Notch signaling 
also leads to the inhibition of tumor growth in a vari-
ety of tumor models [47,  51,  52].  This is probably 
because increased tumor vessels induced by DLL4/
Notch blockade are non-functional vessels resulting in 
tumor hypoxia [47].
Fibroblast Growth Factor (FGF)/ Fibroblast 
Growth Factor Receptor (FGFR) (Fig.  1E)
　 FGF1, FGF2. The FGF/FGFR signaling 
pathway plays an important role in embryonic organo-
genesis [53,  54],  and disturbance of this pathway 
leads to various sorts of developmental defects [55,  
56].  In the adult organism,  FGF/FGFR signaling is 
involved in important physiological processes such as 
the regulation of wound healing and angiogenesis 
[57].
　 FGFs are heparin-binding growth factors that are 
part of a family that includes 23 members,; FGF1-23 
[57].  Only 18 FGF members work as FGF ligands,  
because FGF11,  12,  13,  and 14 are not functional 
ligands for FGFR,  and the FGF15 gene does not exist 
in humans [57].  Among these family members,  FGF1 
and FGF2 are mostly described to possess a potent 
pro-angiogenic eﬀect [58].  They induce the prolifera-
tion and migration of endothelial cells.
　 FGFR. FGFRs belong to a receptor family 
consisting of FGFR-1,  -2,  -3,  and -4 [57].  FGFRs 
are expressed in most cells and have various functions,  
including normal cell growth,  diﬀerentiation,  and 
angiogenesis [59].  In many cancers,  FGFR overex-
pression or mutation is found.  FGFR activation has 
been shown to induce angiogenesis in a cell culture 
model and an animal model [59,  60].
Clinical Application of Targeting 
Angiogenesis
　 Currently,  various antiangiogenic agents are in 
various stages of development.  Among them,  there 
are 5 agents clinically approved by the U.S.  Food and 
Drug Administration (FDA),  bevacizumab,  sorfenib,  
sunitinib,  pazopanib,  and vandetanib.  In this section,  
we will introduce these 5 agents and other antiangio-
genic agents that are currently under investigation.
　 Bevacizumab (VEGF-Aantibody). Bevacizumab 
was approved for clinical use as the ﬁrst antiangio-
genic molecular targeting agent.  Bevacizumab is a 
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Fig. 1　 Schema of receptors and their ligands.  Each part of the ﬁgure represents the relation between a receptor and its ligands.  A,  
Relation between VEGFR-1/-2/-3 and VEGF-A/-B/-C; B,  Relation between Tie1/2 and Ang-1/2; C,  Relation between PDGFRs and 
PDGFs; D,  Relation between Notch and DLL4; E,  Relation between FGFR-1/-2/-3/-4 and FGF-1/-2.
humanized monoclonal antibody against VEGF-A,  
preventing its binding to VEGFR.  In examining the 
eﬃcacy of anti-VEGF-A monoclonal antibody,  it was 
initially reported that the antibody could inhibit sub-
cutaneous tumor growth in a mouse model,  despite its 
lack of eﬃcacy in an in vitro model [61].  In clinical 
study,  the eﬃcacy of bevacizumab is mainly shown in 
combination with various cytotoxic agents; its eﬃcacy 
as a single agent has not been proven [62].  The ﬁrst 
phase 3 trial proving a survival beneﬁt of bevaci-
zumab was conducted in patients with advanced col-
orectal cancer [63].  This study compared irinotecan/
ﬂuorouracil/leucovorin therapy (standard therapy at 
the time) with irinotecan/ ﬂuorouracil /leucovorin 
plus bevacizumab.  The addition of bevacizumab sig-
niﬁcantly improved overall survival (OS) by ﬁve 
months (15.6 months vs.  20.3 months,  p＜0.001).  In 
response to this result,  the FDA approved bevaci-
zumab for the treatment of advanced colorectal cancer.  
After that,  favorable outcome in phase 3 trials was 
proved in various cancers,  including renal cell cancer 
[64] and non-small cell lung cancer [65].
　 Aﬂibercept (VEGF-Trap). Aﬂibercept is 
another type of anti-VEGF-A agent.  It has not yet 
been approved for clinical use.  As stated previously,  
VEGFR-1 has higher aﬃnity to VEGF-A than does 
VEGFR-2.  Aﬂibercept utilizes the VEGFR-1 ligand-
binding domain as a decoy (VEGF-Trap) and,  at ﬁrst,  
was synthesized by combining domain1-3 of VEGFR-1 
and the Fc portion of immunoglobulin G1 (IgG1).  But 
this agent was strongly charged positive and bound 
nonspeciﬁcally to negatively charged cell surfaces.  
Then,  domain 2 of VEGFR-1,  domain 3 of VEGFR-
2,  and the Fc portion of IgG1 were combined,  and this 
improvement allowed aﬂibercept to possess high 
speciﬁcity to VEGF-A.  It was conﬁrmed in a xeno-
graft model that aﬂibercept exerted an antitumor 
effect by inhibiting tumor angiogenesis [66].  
Aﬂibercept is now being evaluated in various phase 3 
studies including ovarian cancer,  non-small cell lung 
cancer,  colorectal cancer,  and prostate cancer.  In a 
phase 2 study of heavily pretreated advanced lung 
adenocarcinoma,  4mg/kg of aﬂibercept showed minor 
single agent activity with 2.7 months of median pro-
gression-free survival (PFS) [67].
　 Sorafenib. Almost all small molecule antian-
giogenic agents are multikinase inhibitors (Table 1),  
and many transmembrane receptors,  including 
VEGFR,  have similar kinase structures.  Due to this 
multitargeting ability,  small molecule antiangiogenic 
agents are not always regarded as a pure inhibitor of 
angiogenesis,  and their eﬃcacy might often be attrib-
uted not to their antiangiogenic eﬀect but to their 
direct antitumor eﬀect.
　 Sorafenib is the ﬁrst small molecule antiangiogenic 
kinase inhibitor improved by the FDA,  and it is now 
clinically used for advanced renal cell carcinoma and 
advanced hepatocellular carcinoma.  Targets of 
sorafenb are VEGFR-2 and -3,  PDGFR-β,  RAF,  and 
c-Kit.  In a phase 3 study of advanced clear-cell renal-
cell carcinoma,  sorafenib reduced the risk of death as 
compared with a placebo (hazard ratio,  0.72; 95ｵ 
CI,  0.54 to 0.94; p＝0.02) [68].  In a similar way,  
sorafenib prolonged OS by 2.8 months compared with 
a placebo for advanced hepatocellular carcinoma (haz-
ard ratio,  0.69; 95ｵ CI,  0.55 to 0.87; p＜0.001) 
[69].
　 Sunitinib. Sunitinib is a multitargeting tyrosine 
kinase inhibitor against VEGFR-1,  -2,  and -3,  
PDGFR-β,  c-Kit,  and rearranged during transfec-
tion (RET) receptor.  Sunitinib was approved for 
imatinib-resistant or imatinib-intolerant gastrointesti-
nal stromal tumors based on the data that sunitinib,  
compared with a placebo,  signiﬁcantly prolonged time 
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Table 1　 Trargets of antiangiogenic agents and their developmental status
Agent Targets Developmental Status
Bevacizumab VEGF-A FDA approved
Aﬂibercept VEGF-A phase 3 study
Sorafenib VEGFR-2, VEGFR-3, PDGFR-β, RAF, c-Kit FDA approved
Sunitinib VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β, c-Kit, RET FDA approved
Pazopanib VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, c-Kit FDA approved
Vandetanib VEGFR-2, EGFR, RET FDA approved
Axitinib VEGFR-1, VEGFR-2, VEGFR-3 phase 3 study
Cediranib VEGFR-1, VEGFR-2, VEGFR-3 phase 3 study
to progression (hazard ratio,  0.33; 95ｵ CI,  0.23 to 
0.47; p＜0.0001) and OS (hazard ratio,  0.49; 95ｵ 
CI,  0.29 to 0.83; p＝0.007) [70].
　 Sunitinib was next proved to be eﬀective against 
metastatic advanced renal-cell carcinoma.  PFS was 
signiﬁcantly longer in the sunitinib group than in the 
interferon α group (11 months vs.  5 months,  hazard 
ratio,  0.42; 95ｵ CI,  0.32 to 0.54; p＜0.001) [71].
　 Pazopanib. Pazopanib targets VEGFR-1,  -2,  
and -3,  PDGFR-α and -β,  and c-Kit [72].  In a 
phase 3 study,  pazopanib demonstrated signiﬁcant 
improvement in PFS and tumor response rate com-
pared with a placebo in treatment-naive and cytokine-
pretreated patients with advanced/metastatic renal 
cell carcinoma (9.2 months vs.  4.2 months,  hazard 
ratio,  0.46; 95ｵ CI,  0.34 to 0.62; p＜0.001) [73].
　 Vandetanib. Vandetanib inhibits VEGFR-2,  
EGFR,  and RET receptor [62,  74].  This agent 
showed promising results against advanced non-small 
cell lung cancer in a phase 2 study [75] and was 
proved to be eﬀective in a phase 3 trial in combination 
with docetaxel [76].  Its beneﬁt was modest,  however,  
and the application for FDA approval in non-small cell 
lung cancer was withdrawn.  However,  there recently 
is a growing awareness of the eﬃcacy of blocking both 
VEGFR-2 and EGFR signaling [77,  78],  because 
EGFR signaling might activate the VEGFR-2 pathway 
[79].  In the Biomarker-integrated Approaches of 
Targeted Therapy for Lung Cancer Elimination 
(BATTLE) trial,  which selected a treatment modality 
depending on the character of the cancer biomarkers,  
lung cancer with expression of VEGFR-2 responded 
well to vandetanib which inhibits both VEGFR-2 and 
EGFR [80].
　 Vandetanib also showed beneﬁts against medullary 
thyroid cancer and was approved by the FDA for the 
treatment of advanced medullary thyroid cancer.
　 Other antiangiogenic tyrosine kinase inhibi-
tors. A great number of other antiangiogenic 
tyrosine kinase inhibitors are currently under investi-
gation.  Axitinib acts against VEGFR-1,  -2,  and -3 
[81].  Recently,  positive phase 3 trial results for 
axitinib in patients with previously treated metastatic 
renal cell carcinoma was reported,  with axitinib sig-
niﬁcantly prolonging PFS compared with sorafenib 
(axis 1032 trial).
　 Cediranib is a VEGFR-2 inhibitor with additional 
inhibition eﬀect against VEGFR-1 and -3 [82].  The 
addition of cediranib to carboplatin/paclitaxel 
improved PFS,  but the toxicity was not acceptable at 
a 30-mg dose [83].  Currently a 20-mg dose of 
cediranib is being examined in the same trial design.
Problems of Antiangiogenic Therapy and 
Future Directions
　 Antiangiogenic therapy has achieved successful 
outcomes in several cancers in both basic and clinical 
study [61,  63,  72,  74,  77,  84-87],  but this therapy 
is faced with emerging issues.  One of them is the lack 
of a biomarker that predicts the eﬃcacy of antiangio-
genic therapy.  Recently,  biomarkers such as serum 
VEGF-A and microvessel density were reported as 
being predictive markers of antiangiogenic therapy 
[88,  89].  Many potent biomarkers must be validated,  
including those markers.  Another issue is acquired 
resistance against antiangiogenic therapy.  At ﬁrst,  
antiangiogenic therapy was believed to rarely cause 
acquired resistance,  because it targets not cancer 
cells themselves,  which are genetically unstable,  but 
genetically stable vascular endothelial cells.  However,  
a recent study reported the emergence of acquired 
resistance to anti-VEGF therapy [90].
　 The era of antiangiogenic therapy has just begun.  
Most of the antiangiogenic agents have focused on the 
VEGF pathway.  But now,  many pathways related to 
tumor angiogenesis have been uncovered,  and many 
agents have been developed that target these pathways.  
The role of antiangiogenesis will become more impor-
tant in cancer therapy.
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